These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30355102)

  • 1. Single-Nucleotide Polymorphism 309T>G in the MDM2 Promoter Determines Functional Outcome After Stroke.
    Rodríguez C; Ramos-Araque ME; Domínguez-Martínez M; Sobrino T; Sánchez-Morán I; Agulla J; Delgado-Esteban M; Gómez-Sánchez JC; Bolaños JP; Castillo J; Almeida A
    Stroke; 2018 Oct; 49(10):2437-2444. PubMed ID: 30355102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
    Zhang X; Pageon L; Post SM
    Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 and its functional polymorphism SNP309 contribute to the development of esophageal carcinoma.
    Xiao FK; Guo S; Yang F; Zhao LS; Wang LD
    J Gene Med; 2019 May; 21(5):e3086. PubMed ID: 30861607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
    Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
    Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
    Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
    Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease.
    Zimmer V; Widmann T; Müller M; Ong MF; Stein JM; Pfreundschuh M; Lammert F; Roemer K; Assmann G
    Digestion; 2010; 81(4):246-51. PubMed ID: 20110711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
    Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
    Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
    Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
    Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
    Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ctnnb1 transcriptional upregulation compensates for Mdm2/p53-mediated β-catenin degradation in neutrophils following cardioembolic stroke.
    Wang H; Zhou K; Li W; Du J; Xiao J
    Gene; 2021 Jan; 766():145022. PubMed ID: 32758579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
    Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
    DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.